Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.

Newell, D R; Pearson, A D; Balmanno, K; Price, L; Wyllie, R A; Keir, M; Calvert, A H; Lewis, I J; Pinkerton, C R; Stevens, M C.

J Clin Oncol ; 11(12): 2314-23, 1993 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-8246021

2.

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.

Wedge, S R; Laohavinij, S; Taylor, G A; Boddy, A; Calvert, A H; Newell, D R.

Clin Cancer Res ; 1(12): 1479-86, 1995 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-9815947

3.

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

Batey, M A; Wright, J G; Azzabi, A; Newell, D R; Lind, M J; Calvert, A H; Boddy, A V.

Eur J Cancer ; 38(8): 1081-9, 2002 May.

Artículo en Inglés | MEDLINE | ID: mdl-12008196

4.

Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.

Calvert, A H; Boddy, A; Bailey, N P; Siddiqui, N; Humphreys, A; Hughes, A; Robson, L; Gumbrell, L; Thomas, H; Chapman, F.

Semin Oncol ; 22(5 Suppl 12): 91-8; discussion 99-100, 1995 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-7481870

5.

Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene.

Calvert, A H; Ghokul, S; Al-Azraqi, A; Wright, J; Lind, M; Bailey, N; Highley, M; Siddiqui, N; Lunec, J; Sinha, D; Boddy, A; Roberts, T; Fenwick, J.

Semin Oncol ; 26(1 Suppl 2): 90-4, 1999 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10190788

6.

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

Clamp, A; Adams, M; Atkinson, R; Boven, E; Calvert, A H; Cervantes, A; Ganesan, T; Lotz, J; Vasey, P; Cheverton, P; Jayson, G C.

Gynecol Oncol ; 95(1): 114-9, 2004 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-15385119

7.

Quinazoline antifolates inhibiting thymidylate synthase: computer modelling of the N10 substituent.

Jones, T R; Betteridge, R F; Neidle, S; Jackman, A L; Calvert, A H.

Anticancer Drug Des ; 3(4): 243-8, 1989 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-2930626

8.

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.

Bowman, K J; Newell, D R; Calvert, A H; Curtin, N J.

Br J Cancer ; 84(1): 106-12, 2001 Jan 05.

Artículo en Inglés | MEDLINE | ID: mdl-11139322

9.

Estimation of glomerular filtration rate in cancer patients.

Wright, J G; Boddy, A V; Highley, M; Fenwick, J; McGill, A; Calvert, A H.

Br J Cancer ; 84(4): 452-9, 2001 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-11207037

10.

Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters.

Mummaneni, V; Kaul, S; Igwemezie, L N; Newell, D R; Porter, D; Thomas, H; Calvert, A H; Winograd, B; Barbhaiya, R H.

J Pharmacokinet Biopharm ; 24(4): 313-25, 1996 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9044163

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: